RxDoctor Payments Data

Stephanie Simonetti

Nurse Practitioner · Cherry Hill, NJNPI 1104586031

Payments from drug & device makers

$1,838in general payments, 2019–2025

Across 85 payments — averaging $21.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$367
  • Amgen$247
  • Teva Pharmaceuticals USA, Inc.$41
  • Astellas Pharma US Inc$17
  • AstraZeneca$14
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$1,838100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,838 in reported general payments places this provider in the 85th percentile of 2,138 nurse practitioner providers in New Jersey.

See all nurse practitioner providers in New Jersey

Medicare billing

Part B allowed, 2024
$39,816
Medicare patients
178
Services billed
386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide84$117,795
JardianceEmpagliflozin45$39,750
MounjaroTirzepatide23$24,376
TrulicityDulaglutide13$22,640
MyrbetriqMirabegron25$20,706
OxycontinOxycodone Hcl11$18,404
FarxigaDapagliflozin Propanediol13$18,032
LinzessLinaclotide11$15,973
Breo ElliptaFluticasone/Vilanterol25$9,835
PremproEstrogen,con/M-Progest Acet14$3,521
Atorvastatin Calcium270$3,247
Albuterol Sulfate HfaAlbuterol Sulfate88$2,755
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$2,635
Omeprazole162$2,549
Levothyroxine Sodium146$1,839

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$367$117,79584 claims
Astellas Pharma US IncMyrbetriq$17$20,70625 claims
AstraZenecaFarxiga$14$18,03213 claims
AbbVieLinzess$1,139$15,97311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,138 nurse practitioner providers in New Jersey.

Other nurse practitioner in Cherry Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →